Treatment for Recurrent Thrush
Initial Treatment Based on Severity
- For mild oropharyngeal thrush, the Infectious Diseases Society of America recommends first-line treatment with Clotrimazole troches (10 mg 5 times daily) or miconazole mucoadhesive buccal 50-mg tablet applied once daily for 7-14 days 1, 2
- For mild oropharyngeal thrush, an alternative treatment is Nystatin suspension (100,000 U/mL) 4-6 mL 4 times daily, or 1-2 nystatin pastilles (200,000 U each) 4 times daily, for 7-14 days 1, 3
- For moderate to severe oropharyngeal thrush, the recommended treatment is oral fluconazole 100-200 mg daily for 7-14 days 1, 2, 3
Management of Recurrent Episodes
- For patients with recurrent oropharyngeal thrush, the Infectious Diseases Society of America strongly recommends chronic suppressive therapy with fluconazole 100 mg three times weekly 1, 3
- For HIV-infected patients with recurrent thrush, antiretroviral therapy is strongly recommended to reduce recurrence 1, 4
- For denture-related candidiasis, proper disinfection of the denture in addition to antifungal therapy is essential 1, 3
Special Considerations
- For denture wearers, proper denture hygiene and disinfection is recommended to prevent recurrent thrush 1, 3
- For immunocompromised patients, treating the underlying immunodeficiency when possible is recommended to reduce recurrence 1, 4
- For diabetic patients, optimizing glycemic control is recommended to prevent recurrent thrush 6
Duration of Therapy
- For acute episodes of oropharyngeal thrush, treatment duration is 7-14 days 1, 3
- For patients with recurrent oropharyngeal thrush and persistent immunosuppression, continued suppression may be needed indefinitely 1, 4
Pitfalls and Caveats
- Failure to identify and address underlying causes may lead to treatment failure 1, 3
- Improper denture care can lead to persistent colonization and recurrent infection 1, 3
- Non-albicans Candida species may be less responsive to fluconazole and require alternative therapies 1, 2
- Patients on long-term suppressive therapy should be monitored for potential drug interactions and hepatotoxicity 1